EN PL
PRACA ORYGINALNA
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Introduction:
This study aimed to investigate the relationship between the pan-immune-inflammation value (PIV), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) and disease activity in rheumatoid arthritis (RA), characterized by chronic inflammation and immune system involvement, and to provide new insights into the clinical implications of RA.

Material and methods:
A total of 148 participants, including 97 RA patients (both newly diagnosed and established cases) and 51 healthy controls, were included in the study. Disease severity was assessed using the Disease Activity Score 28 (DAS28), and the relationship between DAS28 and PIV, SII, and SIRI, obtained from complete blood count results, was investigated. Additionally, C-reactive protein and erythrocyte sedimentation rate measurements were included in the study.

Results:
The average age of RA patients was significantly higher than that of healthy individuals (p = 0.002). A positive correlation was found between the DAS28 score and the inflammation indices (SII, PIV, SIRI), with 65.98% of RA patients in the active phase and 34.02% in remission. Systemic immune-inflammation index had a predictive accuracy of 75.26%, PIV 71.13%, and SIRI 72.16%. The AUC (area under curve) values for SII, PIV, and SIRI were 0.717, 0.719, and 0.717, respectively, with cutoff values of 611.45, 323.88, and 1.18. Sensitivity and specificity were calculated as 57.81% and 60.61% for SII, 60.94% and 63.64% for PIV, and 59.38% and 63.64% for SIRI.

Conclusions:
The findings revealed that PIV, SII, and SIRI were elevated in individuals with RA and may serve as complementary diagnostic markers. PIV, SII, and SIRI, as measures of disease activity in RA, may help monitor treatment efficacy and improve patient prognosis.

REFERENCJE (33)
1.
Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci 2022; 23: 905, DOI: 10.3390/ijms23020905.
 
2.
Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 2020; 9: 880, DOI: 10.3390/cells9040880.
 
3.
Turnbull KS, Perry ME. Advanced therapies in rheumatoid arthritis. In: Translational Autoimmunity. Elsevier 2023; 181–205.
 
4.
Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. Ann Rheum Dis 2022; 81: 1358–1366, DOI: 10.1136/annrheumdis-2022-222586.
 
5.
Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 2021; 397: 305–317, DOI: 10.1016/S0140-6736(20)32341-2.
 
6.
Van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol 2014; 32 (5 Suppl 85): 65–74.
 
7.
Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 1369–1374, DOI: 10.1136/ard.2010.145995.
 
8.
Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal 2021; 35: e23964, DOI: 10.1002/jcla.23964.
 
9.
Ulutaş F, Çobankara V. Pan-immune-inflammation value (PIIV) in lupus nephritis: PIIV as a predictor of reduced GFR. Med Sci Discovery 2023; 10: 234–238.
 
10.
Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammation value and prognosis in patients with esophageal cancer. Ann Surg Open 2022; 3: e113, DOI: 10.1097/AS9. 0000000000000113.
 
11.
Yang XC, Liu H, Liu DC, et al. Prognostic value of pan-immune- inflammation value in colorectal cancer patients: a systematic review and meta-analysis. Front Oncol 2022; 12: 1036890, DOI: 10.3389/fonc.2022.1036890.
 
12.
Liu B, Wang J, Li Y Yan, et al. The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999–2018. Arthritis Res Ther 2023; 25: 34, DOI: 10.1186/s13075-023-03018-6.
 
13.
Satis S. New inflammatory marker associated with disease activity in rheumatoid arthritis: the systemic immune-inflammation index. Curr Health Sci J 2021; 47: 553–557, DOI: 10.12865/CHSJ.47.04.11.
 
14.
Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clinical Cancer Res 2014; 20: 6212–6222, DOI: 10.1158/1078-0432.CCR-14-0442.
 
15.
Chao B, Ju X, Zhang L, et al. A novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients. Front Oncol 2020; 10: 766, DOI: 10.3389/fonc.2020.00766.
 
16.
Pacheco-Barcia V, Solís RM, France T, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in meta­static pancreatic cancer. Pancreatology 2020; 20: 254–264, DOI: 10.1016/j.pan.2019.12.010.
 
17.
Erre GL, Buscetta G, Mangoni AA, et al. Diagnostic accuracy of different blood cells-derived indexes in rheumatoid arthritis: a cross-sectional study. Medicine (Baltimore) 2020; 99: e22557, DOI: 10.1097/MD.0000000000022557.
 
18.
Al-Shemery MK. Risk of incident rheumatoid arthritis related to anemia and associated with CRP. Medico-Legal Update 2020; 20: 41034, DOI: 10.37506/MLU.V20I4.1956.
 
19.
Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007; 66: 407–409, DOI: 10.1136/ard.2006.054205.
 
20.
Tutan D, Doğan AG. Pan-immune-inflammation index as a biomarker for rheumatoid arthritis progression and diagnosis. Cureus 2023; 15: 46609, DOI: 10.7759/cureus.46609.
 
21.
Ulutaş F, Aydın M. Pan-immune-inflammation value in FMF patients. Med Sci Discovery 2023; 10: 364–367.
 
22.
Lee LE, Ahn SS, Pyo JY, et al. Pan-immune-inflammation value at diagnosis independently predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol 2021; 39: S88–S93, DOI: 10.55563/clinexprheumatol/m46d0v.
 
23.
Uzun M, Yıldırım EÇ, Gökcek S, et al. Prognostic Role of Pan Immune Inflammation Value and Systemic Inflammation Response Index in Small Cell Lung Cancer. Acta Oncologica Turcica 2023; 56: 220–228.
 
24.
Ermurat S, Tezcan D. Sistemik lupus eritematozus hastalarında inflamasyon belirteci ve yüksek hastalık aktivite göstergesi olarak yeni hematolojik indeksler. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2022; 48: 189–196 [Article in Turkish].
 
25.
Susok L, Said S, Reinert D, et al. The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy. J Cancer Res Clin Oncol 2022; 148: 3103–3108, DOI: 10.1007/s00432-021-03878-y.
 
26.
Yoshikawa T, Furukawa T, Tamura M, et al. THU0106 systemic immune-inflammatıon index in rheumatoid arthritis patients: relation to disease activity. Ann Rhem Dis 2019; 78: 325, DOI: 10.1136/annrheumdis-2019-eular.4481.
 
27.
Bai J, Tian Y, Wang F, et al. Role of systemic immune-inflammation index (SII) in assessing clinical efficacy of TNF- inhibitors for rheumatoid arthritis. Am J Transl Res 2023; 15: 6524–6533.
 
28.
Fucà G, Guarini V, Antoniotti C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer 2020; 123: 403–409, DOI: 10.1038/s41416-020-0894-7.
 
29.
Guven DC, Sahin TK, Erul E, et al. The association between the pan-immune-inflammation value and cancer prognosis: a systematic review and meta-analysis. Cancers (Basel) 2022; 14: 2675, DOI: 10.3390/cancers14112675.
 
30.
Kayhan S, İsak ÖA. The significance of pan-immune inflammation value and systemic immune inflammation Index in colorectal cancer screening. Turkish Journal of Clinics and Laboratory 2021; 12: 273–727.
 
31.
Ertürk A, Balcı A. Pan-immune-inflammation value and systemic immune-inflammation index: Are they useful markers in sarcoidosis? SII and PIV in sarcoidosis. J Surg Med 2023; 7: 391–397. DOI: https://doi.org/10.28982/josam....
 
32.
Kazan DE, Kazan S. Systemic immune inflammation index and pan-immune inflammation value as prognostic markers in patients with idiopathic low and moderate risk membranous nephropathy. Eur Rev Med Pharmacol Sci 2023; 27: 642–648, DOI: 10.26355/eurrev_202301_31065.
 
33.
Xu Y, He H, Zang Y, et al. Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: a multi-center retrospective study. Clin Rheumatol 2022; 41: 1989–2000, DOI: 10.1007/s10067-022-06122-1.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top